Nan Fung Trinity HK Ltd. Buys New Holdings in Vor Biopharma Inc. $VOR

Nan Fung Trinity HK Ltd. bought a new stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) during the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 721,550 shares of the company’s stock, valued at approximately $13,767,000.

A number of other large investors also recently added to or reduced their stakes in the business. Fulcrum Asset Management LLP bought a new position in Vor Biopharma in the 3rd quarter worth approximately $64,000. Parallel Advisors LLC grew its holdings in Vor Biopharma by 29,640.0% during the 3rd quarter. Parallel Advisors LLC now owns 1,487 shares of the company’s stock valued at $28,000 after buying an additional 1,482 shares in the last quarter. Alps Advisors Inc. grew its holdings in Vor Biopharma by 42.5% during the 3rd quarter. Alps Advisors Inc. now owns 78,371 shares of the company’s stock valued at $1,495,000 after buying an additional 23,373 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Vor Biopharma during the third quarter valued at approximately $58,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock valued at $198,000 after buying an additional 2,171 shares during the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Stock Down 3.8%

Shares of VOR stock opened at $19.32 on Friday. Vor Biopharma Inc. has a 12-month low of $6.50 and a 12-month high of $26.00. The stock’s 50-day moving average price is $20.09 and its 200-day moving average price is $17.50.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Friday, October 30th. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). Equities research analysts predict that Vor Biopharma Inc. will post -2.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a report on Thursday, October 15th. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Wedbush raised their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Finally, Stifel Nicolaus set a $40.00 price target on shares of Vor Biopharma in a report on Monday, November 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma has an average rating of “Buy” and an average target price of $38.29.

Vor Biopharma Profile

Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.